Sentences with phrase «drug development experience»

QUALIFICATIONS: Over twenty years drug development experience ranging from pre-clinical pharmacology / toxicology to managing and directing clinical and cross functional teams in the conduct and execution of global, clinical trials.

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world - class advisors and partners.

Not exact matches

Jennifer has more than 20 years of regulatory experience, integrating regulatory strategy into drug development and precision medicine across multiple therapeutic areas.

In January 2017, SiteOne announced the closing of a research and development agreement with Amgen, a collaboration focused on combining SiteOne's experienced drug discovery team and portfolio of novel Naᵥ1.7 inhibitors with Amgen's neuroscience capabilities.

«Her breadth of experience in biomedical research and development can benefit Exelixis greatly as the company recommits its resources to drug discovery and bolstering its pipeline following the successful ongoing commercialization of its lead medicine, CABOMETYX.»

The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors.

The Minoryx team is made up of a group of drug discovery and development experts with several decades of experience in biotech and pharma.

Experience in orphan disease drug development and an understanding of genetic concepts and molecular biology laboratory techniques is beneficial.

Douglas Loe, healthcare equity analyst with Echelon Wealth Partners, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors.

It tells the story of «the guinea pigs»» the people most likely to be research subjects in Phase I trials, which test the safety of a drug under development by giving it to healthy subjects and examining any side effects they experience.

Taking antibiotics when they are not needed creates additional health risks as it increases the chance a patient will experience an adverse drug reaction, and also leads to the development of antibiotic - resistant bacteria which affects everyone in the community.

This juncture between basic research and the drug development process first began to interest Conley when she was still a postdoc at Michigan, where she had an «amazing experience» in a «world - renowned research lab.»

Development of the drug was stopped after some patients experienced a reduction in cholesterol lowering over time.

It hits many desirable highlights: postdoc experiences as a Fullbright scholar and a visiting scientist at the National Cancer Institute (NCI), many dozens of published papers and patents, and a long list of impressive job titles from drug companies to law and venture capital firms to state economic development organizations.

Given its prolonged development into adulthood, this region is particularly susceptible to being shaped by life experiences in adolescence, such as stress and drugs of abuse.

Understanding the entire drug development process, however, necessitates experience in big pharma.

We had been looking for a senior scientist with experience in high throughput screening (HTS) assay development for a large drug discovery research program.

With our extensive pharmaceutical / biotech drug discovery and development experience, we are well - positioned to drive projects toward an end goal that will ultimately benefit patients.

Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou's research and development of new applications for its gene editing technology.

The SGC is a global network of experienced academic and industry scientists that will contribute expertise in the development of reagents required for target validation and drug discovery.

12 years of expertise in metabolomics for drug discovery in the pharmaceutical industry and in the development of innovative analytical methods for biomarker analysis, with experience in metabolomics and imaging technologies coupling.

She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company, CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with three partnered Phase II clinical programs and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine, Dr. Leahy has more than 25 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic plannDrug Discovery LLC, a company engaged in psychiatric drug discovery with three partnered Phase II clinical programs and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine, Dr. Leahy has more than 25 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planndrug discovery with three partnered Phase II clinical programs and Adjunct Associate Professor of Neuroscience at Mount Sinai School of Medicine, Dr. Leahy has more than 25 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planndrug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning.

Dr. Joyal has over 20 years of drug discovery experience with expertise in cell and molecular biology, particularly in the areas of receptor biology, cell signaling pathways, and assay development.

Having a strong R&D department with great experience and expertise in drug development, animal model and assay development and preclinical efficacy evaluation, the contribution of Biomedcode has been greatly valued by our partners, as documented by our participation in several collaborative research projects.

Experience with DMPK and early drug development in metabolic disease, inflammation and oncology

Jörg brings over 17 years» experience in drug discovery and development across key areas such as oncology, infectious diseases, vaccinology, and autoimmunity, with a focus on peptide and nucleic acid - based therapeutics.

Candidates should have a passion for drug development with extensive experience in IND - filing and early clinical development.

Erik is a biopharmaceutical development and operational professional with more than 20 years of drug development, project management and manufacturing / operational experience in pharmaceutical and biotechnology companies in North America and Europe.

At QPS, translational medicine brings together leading - edge technologies and pharmaceutical R&D experience to create a business service unit that works efficiently to advance your drug development program.

The new advisors, some of the most wellrespected individuals in their fields, were specifically sought for the wealth of experience they bring to bear on Foundation efforts to advance drug development in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texasdevelopment in SMA: Paul S. Anderson, PhD, retired vice president for Chemistry at Merck, G. Stephen DeCherney, MD, MPH, president of Clinical Development Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of TexasDevelopment Services Americas for Quintiles Transnational Corp., Corey S. Goodman, PhD, president and chief executive officer of Renovis, Inc., Jonathan S. Leff, managing director at Warburg Pincus LLC and responsible for the firm's life sciences investment effort, John H. Park, Partner at Blum Capital Partners, LP, and Wesley Thompson, PhD, professor of Neurobiology at The University of Texas at Austin.

The trial is being managed by the charity's highly experienced Drug Development Office.

SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker testing solutions for the fields of oncology, personalized molecular diagnostics ®, and personalized molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.

She has experience in small molecule and large molecule development for both oncology and non-oncology indications and has a strong interest in developing alternative in vitro and in vivo methods to assess safety and efficacy outside of the traditional drug development paradigm.

Dr. Lui has seven years of experience working in preclinical drug development and target validation in academia and industry.

So, whereas the typical person might think of their «environment» as their house, or their neighborhood - scientists trying to understand the factors that influence the development of schizophrenia define environment to include everything from the social, nutritional, hormonal and chemical environment in the womb of the mother during pregnancy, up to the social dynamics and stress a person experiences, to street drug use, education, virus exposure, vitamin use, and much, much more.

For example, the superbug MRSA, which can cause hard - to - treat skin infections, appears to contaminate approximately 5 % of U.S. retail meat; mysterious skin hives or allergic reactions may be a sign of alpha - gal meat allergies; a lack of safety thresholds in U.S. meat for drug residues, toxic metals, and pesticides can potentially result in jaundice and skin cancer; a case of Vitamin A poisoning from fish actually resulted in one man experiencing such serious peeling of his skin it took more than three months to heal; using tanning beds instead of natural sunlight or supplements to get Vitamin D is linked to an increased risk of the deadliest kind of skin cancer; milk consumption has been associated with increased acne risk; and low antioxidants levels in the skin may correlate with the development of wrinkles.

The veterinary leadership experience and the AVMA leadership convention were great experiences as well; they really helped with my leadership development, really helped with my networking, and meeting veterinarians all ready out in the profession and in the various industries, like in the drug companies and along those lines.

By maintaining a commitment to continuous improvement, promoting the professional development of our employees, and continuing our dedication to quality and customer service, Diamondback Drugs will offer a «best in class» customer experience.

She has more than 30 years of experience working with pharmaceutical companies and the FDA in product discovery, protocol review and new drug development.

It's almost like their development teams build the characters, stories, and battle system and then smoke a bunch of crack and decide in a drugged up haze on a range of other features that will «enhance» the experience.

An experienced drug injury lawyer needs to stay on top of investigative developments and new information that comes to light.

Key developments in the case law reflect trends that employers are experiencing: sexual harassment, drug testing and addressing mental health in the workplace.

Her experience in Government includes initiatives such as the development of the Provincial Immigration strategy, the establishment of the Global Food Institute, the Sylvia Fedoruk Canadian Centre for Nuclear Innovation, establishment of Innovation Saskatchewan, construction of the first Women's Shelter built by the Provincial Government since 1989, the creation of the Office of the Counsel for Children, and changes to the Human Rights Code regarding transgender persons and Kate's Place, a supportive residence for women who are attending Regina Drug Treatment Court.

Our team of experienced trial and appellate lawyers craft and execute comprehensive intellectual property strategies from initial drug development through trial and appeal.

Summary: Experienced cell / molecular biologist with background in bioanalytics, cell - based & ligand bind - ing assay development / validation, early discovery of therapeutic biologics and anticancer drugs.

Chemical engineer professional with experience in research and drug development, member of the scientific community, looking for a job as chemical engineer in a prestigious pharmaceutical company that can offer me the opportunity to develop professionally.

• Highly experienced in the assessment of patient care needs and development of nursing care plans, particularly providing acute care for a diverse population including patients experiencing drug and alcohol withdrawal, wound care, oncology and dialysis • Proficient in handling details of medical administration and providing assistance in emergency cases.

Bringing 6 years» hands - on experience in developing and implementing core programs to meet the needs of young people, pertaining to education, self - development, homelessness, family ties, and drug and alcohol abuse.

She is responsible for sales, business development, marketing, and client success and has 25 years of experience in background screening, drug testing, and occupational health testing.

Worldwide About Blog Camargo Pharmaceutical Services is the most experienced global strategist providing comprehensive drug development services specialized for the 505 (b)(2) approval pathway and global equivalent processes.